These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28033253)

  • 1. Postoperative cognitive changes after total knee arthroplasty under regional anesthesia.
    Jeon YT; Kim BG; Park YH; Sohn HM; Kim J; Kim SC; An SS; Kim S
    Medicine (Baltimore); 2016 Dec; 95(52):e5635. PubMed ID: 28033253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid aβ to tau ratio and postoperative cognitive change.
    Xie Z; McAuliffe S; Swain CA; Ward SA; Crosby CA; Zheng H; Sherman J; Dong Y; Zhang Y; Sunder N; Burke D; Washicosky KJ; Tanzi RE; Marcantonio ER
    Ann Surg; 2013 Aug; 258(2):364-9. PubMed ID: 23732272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study.
    Eckerström M; Nilsson S; Zetterberg H; Blennow K; Grahn A
    Sci Rep; 2020 Dec; 10(1):22400. PubMed ID: 33372192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in plasma and cerebrospinal fluid biomarkers in aged patients with early postoperative cognitive dysfunction following total hip-replacement surgery.
    Ji MH; Yuan HM; Zhang GF; Li XM; Dong L; Li WY; Zhou ZQ; Yang JJ
    J Anesth; 2013 Apr; 27(2):236-42. PubMed ID: 23085747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between cerebrospinal fluid biomarkers of neuronal injury or amyloidosis and cognitive decline after major surgery.
    Danielson M; Wiklund A; Granath F; Blennow K; Mkrtchian S; Nellgård B; Oras J; Fagerlund MJ; Granström A; Schening A; Rasmussen LS; Harris HE; Zetterberg H; Ricksten SE; Eriksson LI
    Br J Anaesth; 2021 Feb; 126(2):467-476. PubMed ID: 33183737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Associations Between Cognitive Dysfunction, Stress Biomarkers, and Administered Anesthesia Type in Total Knee Arthroplasties: Prospective, Randomized Trial.
    Edipoglu IS; Celik F
    Pain Physician; 2019 Sep; 22(5):495-507. PubMed ID: 31561651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF Beta-amyloid 1-42 Concentration Predicts Delirium Following Elective Arthroplasty Surgery in an Observational Cohort Study.
    Cunningham EL; McGuinness B; McAuley DF; Toombs J; Mawhinney T; O'Brien S; Beverland D; Schott JM; Lunn MP; Zetterberg H; Passmore AP
    Ann Surg; 2019 Jun; 269(6):1200-1205. PubMed ID: 31082921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
    Reijs BLR; Ramakers IHGB; Köhler S; Teunissen CE; Koel-Simmelink M; Nathan PJ; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Vandenberghe R; Johannsen P; Blackwell A; Vanderstichele H; Verhey F; Visser PJ
    J Alzheimers Dis; 2017; 60(3):1119-1128. PubMed ID: 28984585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minor neuropsychological deficits in patients with subjective cognitive decline.
    Wolfsgruber S; Kleineidam L; Guski J; Polcher A; Frommann I; Roeske S; Spruth EJ; Franke C; Priller J; Kilimann I; Teipel S; Buerger K; Janowitz D; Laske C; Buchmann M; Peters O; Menne F; Fuentes Casan M; Wiltfang J; Bartels C; Düzel E; Metzger C; Glanz W; Thelen M; Spottke A; Ramirez A; Kofler B; Fließbach K; Schneider A; Heneka MT; Brosseron F; Meiberth D; Jessen F; Wagner M;
    Neurology; 2020 Sep; 95(9):e1134-e1143. PubMed ID: 32636322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment.
    Gonzales MM; Insel PS; Nelson C; Tosun D; Schöll M; Mattsson N; Sacuiu S; Bickford D; Weiner MW; Mackin RS;
    Int J Geriatr Psychiatry; 2018 Oct; 33(10):1305-1311. PubMed ID: 29953668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid-β₄₂ is associated with cognitive impairment in healthy elderly and subjective cognitive impairment.
    Rolstad S; Berg AI; Bjerke M; Blennow K; Johansson B; Zetterberg H; Wallin A
    J Alzheimers Dis; 2011; 26(1):135-42. PubMed ID: 21593572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project.
    Verberk IMW; Hendriksen HMA; van Harten AC; Wesselman LMP; Verfaillie SCJ; van den Bosch KA; Slot RER; Prins ND; Scheltens P; Teunissen CE; Van der Flier WM
    Neurobiol Aging; 2020 May; 89():99-107. PubMed ID: 32081465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.
    Liu C; Cholerton B; Shi M; Ginghina C; Cain KC; Auinger P; ; Zhang J
    Parkinsonism Relat Disord; 2015 Mar; 21(3):271-6. PubMed ID: 25596881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
    Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M
    Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.